ethyl (2E)-chloro[(2,4-dichlorophenyl)hydrazono]acetate | 27143-12-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ethyl (2E)-chloro[(2,4-dichlorophenyl)hydrazono]acetate
• 英文别名: ethyl (2Z)-2-chloro-2-[(2,4-dichlorophenyl)hydrazinylidene]acetate
• CAS: 27143-12-0
• 化学式: C₁₀H₉Cl₃N₂O₂
• 分子量: 295.553
• InChiKey: MTWAKBYVMJYUSU-DHDCSXOGSA-N

物化性质

• 熔点：
  98 °C
• 沸点：
  358.7±52.0 °C(Predicted)
• 密度：
  1.43±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  50.7
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  ethyl (2E)-chloro[(2,4-dichlorophenyl)hydrazono]acetate 生成 Ethyl 1-(2,4-dichlorophenyl)-5-methoxy-5-t-butylpyrazoline-3-carboxylate
  参考文献：
  名称：

  SOHN, ERICH;ROSCH, WOLFGANG;BAUER, KLAUS;BIERINGER, HERMANN

  摘要：

  DOI：
• 作为产物：
  描述：

  、 2-氯乙酰乙酸乙酯 在 sodium acetate 作用下， 以 乙醇 为溶剂， 反应 1.0h， 生成 ethyl (2E)-chloro[(2,4-dichlorophenyl)hydrazono]acetate
  参考文献：
  名称：

  Active substance combination for the treatment of diabetes

  摘要：

  本发明涉及一种活性物质组合，包括至少一种取代吡唑啉化合物和至少一种药物，用于治疗糖尿病，包括该活性物质组合的药物、包括该活性物质组合的制药配方以及利用该活性物质组合制造药物的用途。

  公开号：

  EP1946778A1

文献信息

• Substituted pyrazoline compounds, their preparation and use as medicaments with ACAT inhibition activity
  申请人：Laboratorios del Dr. Esteve S.A.

  公开号：EP1947087A1

  公开（公告）日：2008-07-23

  The present invention relates to substituted pyrazoline compounds, methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans and animals, especially in dyslipidaemia.

  本发明涉及替代吡唑啉化合物，其制备方法，包含这些化合物的药物，以及它们用于制备用于治疗人类和动物，特别是在血脂异常方面的药物的用途。
• Octahydropentalene-Substituted Pyrazoline Derivatives, Their Prepartion and Use as Medicaments
  申请人：Torrens Jover Antonio

  公开号：US20090054509A1

  公开（公告）日：2009-02-26

  The present invention relates to octahydropentalene-substituted pyrazoline compounds of formula I, methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans and animals. (1)

  本发明涉及式I的八氢松环戊二烯取代的吡唑啉化合物，其制备方法，包含这些化合物的药物以及它们用于制备用于治疗人类和动物的药物的用途。(1)
• Azepane- or Azocane-Substituted Pyrazoline Derivatives, Their Preparation and Use as Medicaments
  申请人：Torrens Jover Antonio

  公开号：US20080269201A1

  公开（公告）日：2008-10-30

  The present invention relates to Azepane- or Azocane-substituted substituted pyrazoline compounds of formula (I), methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans and animals

  本发明涉及公式（I）的氮杂环庚烷或氮杂环庚烷取代的吡唑啉化合物，其制备方法，包含这些化合物的药物以及它们用于制备用于治疗人类和动物的药物的用途。
• Pyrazole Derivatives as Cb1 Modulators
  申请人：Cheng Leifeng

  公开号：US20080287517A1

  公开（公告）日：2008-11-20

  The present invention relates to compounds of formula I wherein R 1 represents a group R 5 O— in which R 5 represents a C 3-7 alkyl group substituted by one or more fluoro or R 5 represents a C 3-7 alkylsulphonyl group which is optionally substituted by one or more fluoro; R 2 represents a C 1-4 alkyl group, hydroxy, fluoro, chloro or cyano wherein each R 2 is independently selected when n is >1; R 3 represents a) cyclohexyl optionally substituted by one or more of the following: hydroxy, fluoro, amino, mono or diC 1-3 alkylamino, carboxy or a C 1-4 alkoxycarbonyl group b) piperidino substituted by one or more hydroxy c) unsubstituted piperidino but only when one of the following applies: R 4 represents cyano or R 1 represents 3-fluoropropylsulphonyloxy or R 1 represents 3,3,3-trifluoropropoxy or R 1 represents 3-fluoropropoxy or R 2 is methyl d) phenyl substituted by one or more of the following: hydroxy, halo or a C 1-4 alkyl group e) pyridyl substituted by a C 1-4 alkyl group or f) a C 4-9 alkyl group; R 4 represents cyano or methyl; and n is 1, 2 or 3 and pharmaceutically acceptable salts thereof and processes for preparing such compounds, their use in the treatment of obesity, psychiatric and neurological disorders, to methods for their therapeutic use and to pharmaceutical compositions containing them.

  本发明涉及一种式I的化合物，其中R1表示R5O-基团，其中R5表示一个C3-7烷基基团，该基团被一个或多个氟代或R5表示一个C3-7烷基磺酰基团，该基团可被一个或多个氟代取代；R2表示C1-4烷基基团，羟基，氟，氯或氰，其中当n>1时，每个R2是独立选择的；R3表示a)环己基，可选地被以下一种或多种取代：羟基，氟，氨基，单或双C1-3烷基氨基，羧基或C1-4烷氧羰基基团b)哌啶取代的羟基或多个羟基c)未取代的哌啶，但仅当以下之一适用时：R4表示氰基或R1表示3-氟丙基磺酰氧基或R1表示3,3,3-三氟丙氧基或R1表示3-氟丙氧基或R2为甲基d)苯基，可选地被以下一种或多种取代：羟基，卤素或C1-4烷基基团e)吡啶基，取代为C1-4烷基基团或f)C4-9烷基基团；R4表示氰基或甲基；n为1、2或3，以及其药学上可接受的盐和制备这种化合物的过程，它们在肥胖症、精神和神经疾病的治疗中的用途，以及它们的治疗用途的方法和包含它们的制药组合物。
• Cycloalkane-Substituted Pyrazoline Derivatives, Their Preparation and Use as Medicaments
  申请人：Torrens Jover Antonio

  公开号：US20080293797A1

  公开（公告）日：2008-11-27

  The present invention relates to Cycloalkane-substituted pyrazoline compounds of formula (I), methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans and animals.

  本发明涉及Cycloalkane-取代的吡唑烷化合物的化学式（I），其制备方法，包含这些化合物的药物以及它们用于制备用于治疗人类和动物的药物的用途。